Sanara MedTech Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026
MWN-AI** Summary
Sanara MedTech Inc. (Nasdaq: SMTI), a Fort Worth-based medical technology company, is set to announce its financial results for the fourth quarter and full year 2025 on March 24, 2026, prior to the opening of U.S. markets. The company specializes in developing and commercializing innovative technologies aimed at enhancing clinical outcomes while lowering healthcare costs in the surgical landscape. A conference call and webcast will take place the same day at 8:00 a.m. ET, where management will discuss the financial results and host a question-and-answer session.
Sanara MedTech offers a diverse portfolio of surgical products tailored for the North American surgical tissue repair market. Their notable offerings include CellerateRX® Surgical Activated Collagen® Powder, BIASURGE® Advanced Surgical Solution, and several advanced biologic products such as ACTIGEN® Verified Inductive Bone Matrix and TEXAGEN® Amniotic Membrane Allograft. The company aims to address the complexities of surgical procedures through its commitment to delivering more effective solutions and maintaining strict regulatory compliance throughout product development.
Investors and interested parties are encouraged to participate in the forthcoming call by dialing the provided toll-free number or accessing the live webcast via the company’s Investor Relations website. A replay of the event will also be available for a limited time following the broadcast.
Sanara MedTech is focused on fostering innovation in surgical care and continues to seek opportunities for growth and expansion within its product lines. This ongoing commitment to research development underscores the company’s potential to navigate the competitive landscape of healthcare technology and deliver meaningful outcomes for patients requiring surgical interventions. For more information, visit SanaraMedTech.com.
MWN-AI** Analysis
As Sanara MedTech Inc. (Nasdaq: SMTI) approaches the announcement of its fourth quarter and full year 2025 financial results on March 24, 2026, several key factors warrant consideration for potential investors.
Sanara is positioned in the promising surgical technology market, focusing on innovative products designed to enhance clinical outcomes while curbing healthcare costs. Its portfolio includes key offerings like CellerateRX® and BIASURGE®, which have gained traction in the North American surgical tissue repair market. Notably, as healthcare providers increasingly seek cost-effective solutions, companies like Sanara could benefit from heightened demand.
Investors should closely monitor Sanara's revenue trajectory leading to this earnings announcement. Analysts will scrutinize overall revenue growth, profitability metrics, and product adoption rates. A strong performance could coincide with the ongoing shift towards outpatient surgical procedures, which may expand the company’s market reach.
Moreover, anticipated developments in new products and innovations will play a vital role in shaping the earnings call narrative. Any updates on regulatory approvals or strategic partnerships could bolster investor confidence. Given the inherent risks detailed in their forward-looking statements, such as competition and regulatory hurdles, a cautious approach is advisable.
Valuation metrics leading up to March 24 will also be crucial. Analysts should analyze the company's Price-to-Earnings (P/E) ratio in comparison to industry standards. If the valuation appears favorable relative to its growth potential, Sanara may present an attractive investment opportunity.
In conclusion, while growth prospects in surgical technologies are robust, investors should maintain a vigilant eye on Sanara's performance metrics during the upcoming earnings call. A well-rounded assessment of both financial outcomes and strategic initiatives will provide clearer insights into the company’s future potential.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
FORT WORTH, TX, March 03, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, announced today that it will report its fourth quarter and full year 2025 financial results on Tuesday, March 24, 2026 before the U.S. financial markets open.
The Company will host a conference call and webcast on March 24, 2026 at 8:00 a.m. Eastern Time to discuss the results of the quarter and full year ended December 31, 2025 and hold a question and answer session at the end of the call. The toll-free number to call for this teleconference is 888-506-0062 (international callers: 973-528-0011) and the access code is 658106. A telephonic replay of the conference call will be available through Tuesday, April 07, 2026, by dialing 877-481-4010 (international callers: 919-882-2331) and entering the replay passcode: 53559.
A live webcast of Sanara’s conference call is accessible by clicking here and will be made available under the “Events” section of the Company’s Investor Relations website, https://ir.sanaramedtech.com/. An online replay will be available for approximately one year following the conclusion of the live broadcast.
About Sanara MedTech Inc.
Sanara MedTech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. The Company develops, markets and distributes surgical products for use by physicians and clinicians in hospitals. Each of the Company’s products and technologies are designed to achieve the goal of providing better clinical outcomes at a lower overall cost for patients. Sanara’s products are primarily sold in the North American surgical tissue repair market. Sanara markets and distributes CellerateRX® Surgical Activated Collagen® Powder, BIASURGE® Advanced Surgical Solution, FORTIFY TRG® Tissue Repair Graft and FORTIFY FLOWABLE® Extracellular Matrix, as well as a portfolio of advanced biologic products including: ACTIGEN® Verified Inductive Bone Matrix, ALLOCYTE® Plus Advanced Viable Bone Matrix, BiFORM® Bioactive Moldable Matrix and TEXAGEN® Amniotic Membrane Allograft to the surgical market. The Company believes it can drive its pipeline from concept to preclinical and clinical development while meeting quality and regulatory requirements. The Company strives to be one of the most innovative and comprehensive providers of effective surgical solutions and is continually seeking to expand its offerings for patients requiring treatments in the United States. For more information, please visit SanaraMedTech.com.
Information about Forward-Looking Statements
The statements in this press release that do not constitute historical facts are “forward-looking statements,” within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. These statements may be identified by terms such as “aims,” “anticipates,” “believes,” contemplates,” “continue,” “could,” “estimates,” “expects,” “forecast,” “guidance,” “intends,” “may,” “plans,” “possible,” “potential,” “predicts,” “preliminary,” “projects,” “seeks,” “should,” “targets,” “will” or “would,” or the negatives of these terms, variations of these terms or other similar expressions. These forward-looking statements include, among others, statements regarding the Company’s business strategy and mission, the development of new products, the timing of commercialization of the Company’s products, and the regulatory approval process. These items involve risks, contingencies and uncertainties such as uncertainties associated with the development and process for obtaining regulatory approval for new products, the extent of product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, uncertainties associated with the development and process for obtaining regulatory approval for new products, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company’s filings with the Securities and Exchange Commission, which could cause the Company’s actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements.
All forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to revise any of these statements to reflect future circumstances or the occurrence of unanticipated events, except as required by applicable securities laws.
Investor Relations Contact:
Jack Powell or Mike Piccinino, CFA
ICR Healthcare
IR@sanaramedtech.com
FAQ**
What key financial metrics should investors expect from Sanara MedTech Inc. SMTI in the fourth quarter and full year 2025 results, as discussed in the upcoming conference call on March 24, 2026?
How does Sanara MedTech Inc. SMTI plan to navigate the competitive landscape in the surgical market with its innovative product offerings?
What factors could potentially impact Sanara MedTech Inc. SMTI's projections for product demand and regulatory approval timelines, as mentioned in their forward-looking statements?
Can investors anticipate any significant updates regarding Sanara MedTech Inc. SMTI's product pipeline and future development plans during the March 22026 conference call?
**MWN-AI FAQ is based on asking OpenAI questions about Sanara MedTech Inc. (NASDAQ: SMTI).
NASDAQ: SMTI
SMTI Trading
6.95% G/L:
$20.17 Last:
88,932 Volume:
$20 Open:
